- Home
- PCM vs ECOR Comparison
PCM vs ECOR Comparison
Compare PCM & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCM | ECOR |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 81.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PCM | ECOR |
|---|---|---|
| Price | $5.66 | $9.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 42.8K | ★ 73.6K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,032,000.00 |
| Revenue This Year | N/A | $33.60 |
| Revenue Next Year | N/A | $30.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 27.20 |
| 52 Week Low | $5.48 | $4.41 |
| 52 Week High | $6.76 | $10.50 |
Technical Indicators
Market Signals| Indicator | PCM | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 76.90 |
| Support Level | $5.65 | $5.70 |
| Resistance Level | $5.83 | $10.43 |
| Average True Range (ATR) | 0.08 | 0.82 |
| MACD | 0.01 | 0.47 |
| Stochastic Oscillator | 40.00 | 94.78 |
Price Performance
Historical ComparisonAbout PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About ECOR electroCore Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.